The bedside Schwartz equation has long been and still is the recommended equation to estimate glomerular filtration rate (GFR) in children. However, this equation is probably best suited to estimate GFR in children with chronic kidney disease (reduced GFR) but is not optimal for children with GFR .75 mL/min/1.73 m 2 . Moreover, the Schwartz equation requires the height of the child, information that is usually not available in the clinical laboratory. This makes automatic reporting of estimated glomerular filtration rate (eGFR) along with serum creatinine impossible. As the majority of children (even children referred to nephrology clinics) have GFR .75 mL/min/1.73 m 2 , it might be interesting to evaluate possible alternatives to the bedside Schwartz equation. The pediatric form of the Full Age Spectrum (FAS) equation offers an alternative to Schwartz, allowing automatic reporting of eGFR since height is not necessary. However, when height is involved in the FAS equation, the equation is essentially equal to the Schwartz equation for children, but there are large differences for adolescents. Combining standardized biomarkers increases the prediction performance of eGFR equations for children, reaching P10 z 45% and P30 z 90%. There are currently good and simple alternatives to the bedside Schwartz equation, but the more complex equations combining serum creatinine, serum cystatin C, and height show the highest accuracy and precision. 2 The height of the child serves as surrogate for muscle mass, since creatinine, which is a breakdown product of muscle mass, changes during growth of the child. The Schwartz formula has been recommended by KDIGO to estimate GFR in children. One downside of this equation is the need for the height of the child, which is commonly not available in the clinical laboratory, making automatic reporting of estimated glomerular filtration rate (eGFR) along with Scr impossible. Automatic reporting of eGFR for adults is mandatory in many countries, allowing early identification of patients with chronic kidney disease (CKD), with evidence demonstrating the benefits of early referrals.
BACKGROUND
Estimating glomerular filtration rate (GFR) in children has a 40-year-old history, dating back to 1976 when Schwartz and colleagues 1 published his very simple bedside formula eGFR ¼ 0.55 3 L/Scr, where L is the height of the child and Scr represents serum creatinine (Scr) expressed in mg/dL. The coefficient of 0.55 has been replaced by 0.413 for children and adolescents, when isotope dilution mass spectroscopy (IDMS) standardized assays for Scr became available. 2 The height of the child serves as surrogate for muscle mass, since creatinine, which is a breakdown product of muscle mass, changes during growth of the child. The Schwartz formula has been recommended by KDIGO to estimate GFR in children. One downside of this equation is the need for the height of the child, which is commonly not available in the clinical laboratory, making automatic reporting of estimated glomerular filtration rate (eGFR) along with Scr impossible. Automatic reporting of eGFR for adults is mandatory in many countries, allowing early identification of patients with chronic kidney disease (CKD), with evidence demonstrating the benefits of early referrals. 3 Indeed, in adults, evidence-based strategies have been shown to prevent progression of CKD. 4 The rationale for automatic reporting in children is less clear, since there are multiple risk factors, such as hypertension and proteinuria, for progression of CKD in children. Moreover, the incidence of CKD in children is much lower than in the adult population. However, early reporting of decreased eGFR may allow early detection and intervention which can only be to the benefit of the child.
In a recent overview, Pottel 5 has extensively reported on the different eGFR equations for children, and therefore, in this review, we will focus on alternative equations applicable to (multiple) biomarkers for standardized assays only. We then give specific insights comparing the bedside Schwartz equation with the pediatric part of the Full Age Spectrum (FAS) equation. Next, we elaborate on the possibility to define kidney function based on the reference interval of single biomarkers or the combination of biomarkers, without using eGFR equations. Finally, we present the prediction performance of eGFR equations combining multiple (standardized) biomarkers, namely Scr and serum cystatin C (ScysC), using real measured GFR data as comparison.
REFERENCE METHOD, STANDARDIZED Scr, AND CYSTATIN C
The gold standard method to obtain measured GFR (mGFR) is kidney clearance of inulin, but several reference methods have shown acceptable accuracy with sufficient scientific evidence. 6 The mGFR data used in this article have been obtained by the gold standard inulin kidney clearance method or by iohexol or 51 Cr-EDTA plasma clearance, using the slope-intercept method followed by the Br€ ochner-Mortensen correction. 7 Standardization of Scr assays with reference to the gold standard IDMS method has been introduced some 10-15 years ago. Most enzymatic Scr assays are nowadays equivalent to the IDMS method. The data used in this article were all obtained with IDMS traceable enzymatic Scr assays, and it should be emphasized that this is critically important for children that have lower Scr values, requiring high accuracy and precision results. 8 Indeed, compensated Jaffe assays may give negative Scr concentrations after compensation (¼ subtracting a constant value) in very young children. Limits of quantitation of the assays should be as low as 0.15 mg/dL, since newborns typically have Scr values of about 0.23 mg/dL 1 month after birth. 9 Many clinical laboratories still use the Jaffe-type Scr assays instead of enzymatic Scr assays due to the higher cost of the latter, but the gap becomes smaller and more and more laboratories switch to enzymatic assays, especially for children.
The situation is different for ScysC. In 2010, there became a certified standard available (ERM-DA471/IFCC) 10 against which ScysC-assays could be calibrated, and only very recently a candidate isotope dilution mass spectrometry method for cystatin C was presented and can potentially serve as gold standard method. 11 Part of the data in this study were obtained with the calibrated particle enhanced turbidimetric (PETIA, Tina quantÒ) assay of Roche, and part of the data were obtained with the calibrated particle enhanced nephelometric (PENIA) method of Siemens. Calibration of cystatin C assays is as essential as for Scr. Although there is still work to do, as the current certified material is about five times higher than the "normal" cystatin C values, and only a one-point calibration is applied, it has been shown that calibration against the certified material reduces variability and increases accuracy. [11] [12] MULTIPLE BIOMARKER EQUATIONS To our knowledge, there are only a very limited number of combined Scr and ScysC-based eGFR equations for children available that were obtained with reference to IDMS traceable Scr and the certified standard for ScysC. Although the best performing combined Schwartz equation was based on height, Scr, ScysC, blood urea nitrogen, and gender, ScysC was not calibrated against the certified standard when this equation was derived. This complex Schwartz formula was originally published in 2009 using turbidimetric ScysC values 13 27 and extended by Hoste and colleagues 28 to adolescents in 2015 and is now extended to the full age spectrum. 22 It has been shown that this concept also applies for other biomarkers: Scr/Q crea can be replaced by ScysC/Q cysC or a combination of both biomarkers, for example, the average of both normalized biomarkers: (Scr/Q crea 1 ScysC/Q cysC )/2. In case of ScysC, the normalization factor Q cysC ¼ 0.82 mg/L 23 ( Table 1) . Other eGFR equations have been developed for children, but none of them combines standardized Scr and ScysC in one equation for children. However, it has recently been shown that combining the Scr-based revised Lund-Malm€ o (LM-REV) equation 29 with the ScysC-based CAPA equation 30 also shows higher accuracy and precision than any single biomarker-based equation. 31 The LM-REV equation and CAPA equation are also presented in Table 1 .
Combining LM-REV with CAPA simply means to take the mean of both equations: (LM-REV 1 CAPA)/2.
Contrary to the FAS equation, which is based on the concept that mean normalized Scr matches mean GFR, the LM-REV and CAPA equations, like all other eGFR equations, have been derived from statistical modeling of measured GFR data against Scr (or ScysC) and demographic variables.
In the following sections, we focus on the popular bedside Schwartz equation and compare it to the pediatric FAS equation, find out the benefits of using combined biomarkers as such and combined biomarker equations, by comparing the combined Schwartz equation, the combined FAS equation, and the combination of Lund-Malm€ o and CAPA to measured GFR.
COMPARING THE SIMPLE BEDSIDE Scr-BASED SCHWARTZ WITH FAS
The normalization factor Q crea in the pediatric FAS equation can be obtained in two different ways: (1) Q crea can be considered as the mean Scr value of the age-specific distribution of healthy children, but (2) Q crea can also be matched to the height of the child, by use of growth curves (Table 2) . Table 2 should be interpreted with caution, as these values have been determined in a Belgian population of healthy children. The mean Scr values were obtained from a large hospital database 9 which was subdivided according to age/gender. For each 1-year age period, the Scr values of healthy children were selected and the mean/median (which is the same when the distribution is Gaussian) is presented as Q crea in Table 2 . National Belgian growth curves 32 were used to match age with mean height of the children. To estimate GFR from Scr, there are two possibilities: either the Q crea corresponding to the age of the child can be considered or the Q crea corresponding to the height of the child can be chosen, which are not necessarily the same for a child at a specific age with a specific height. This is especially true during adolescence, where children may be variable in height at the same age. Height is probably a better indicator for muscle mass and thus for the corresponding Scr value. This is also the reason Hoste and colleagues 28 have modeled the Q crea values against age, and Q crea against height, to allow interpolation (to predict Q crea for values in between the values in Table 2 ), resulting in 4th degree polynomials ( Table 1 ).
Note that there are two polynomials for Q crea (Age) due to the difference between adolescent males and females, that is, adolescent males gain muscle mass in a much faster way than females in this age period, starting from Q crea ¼ 0.61 mg/dL at 14 years of age, on average, and reaching the average plateau value of 0.90 mg/dL, whereas females only reach the value of 0.70 mg/dL. Q crea (height) could be modeled in one 4th degree polynomial, showing that height is a better surrogate than age for gaining muscle mass, as it is independent of gender.
The pediatric part of the FAS equation can be rewritten as FAS crea ¼ 107.3 3 Q crea /Scr. As the Schwartz equation also estimates GFR, it follows that 107.3 3 Q crea ¼ 0.413 3 L. As both equations have been derived in a totally different way and from totally different data sets (Pottel used healthy children and Schwartz used growth-retarded kidney diseased children), the discrepancy between both equations should not be surprising. Figure 1 presents 34 She found that for girls and boys ,13 years, the coefficient is 0.368 and 0.413 for boys $13 years. Based on this analysis, we may conclude that the Schwartz coefficient is probably a little bit too high for (healthy) younger children and needs to be optimized for adolescents, which is not surprising since the data used by Schwartz only contained children up to 16 years of age.
In Figure 2 , we plotted 107.3 3 Q crea /L vs the height of the child, showing that the Schwartz coefficient of 0.413 (or 0.385, according to FAS) is more or less valid for children with height ,165 cm, which is mostly true for girls and boys ,13 years, corresponding to the Schwartz-Lyon modification. Male adolescents are clearly a much more difficult population to model in a simple eGFR equation, with more pronounced differences between Schwartz, at the average Scr value for the average height at the age of 18 years.
COMBINING BIOMARKERS Scr AND ScysC
As the form of the FAS equation is valid for both normalized biomarkers, it is easy to understand that the same estimated GFR can only be obtained from both biomarkers, when Scr/Q crea ¼ ScysC/Q cysC ¼ (Scr/Q crea 1 ScysC/ Q cysC )/2. It also follows that the ratio of FAS cysC /FAS crea is equal to the (reciprocal) ratio of the normalized biomarkers: [Scr/Q crea ]/[ScysC/Q cysC ]. Therefore, when the estimated GFR from Scr (FAS crea ) differs significantly from the estimated GFR from ScysC (FAS cysC ), this is an immediate consequence of the difference between normalized biomarkers. [36] [37] To demonstrate the above reasoning, we plotted ScysC/ Q cysC against Scr/Q crea in Figure 3 for n ¼ 845 measurements of children between 2 and 18 years of age. This data set has been previously described [36] [37] and contains serial measurements of n ¼ 368 children, a data set with unique measurements only, used and described before [15] [16] to compare eGFR equations. It has been shown previously that both normalized and rescaled biomarkers share the same common reference interval of (0.67-1.33). 23, [36] [37] A very simple approach to define or diagnose kidney disease in children would be to consider whether the normalized biomarker is within the reference interval of (0.67-1.33) ( Table 3 ). We applied that rule to a cohort of 845 measurements on children aged between 2 and 18 years. Children with biomarker values within the reference interval have indeed mean mGFR values which are not different from 107.3 mL/min/1.73 m 2 , the value predicted by the FAS equation at the mean Scr ¼ Q crea or ScysC ¼ Q cysC level. Table 3 also shows that Scr/Q crea is approximately equal to "1," the mean Scr value for healthy children. The deviation by 7% from "1" for ScysC/Q cysC might be due to the not optimal normalization factor of 0.82 mg/L that has been used or it may be due to the specific data set, as all children were from nephrology clinics with specific underlying (kidney) pathologies. We can also not rule out assay-related reasons for this deviation (calibration issues, differences between Roche and Siemens assays). We defined the kidney function as "abnormal" when the normalized biomarker was greater than 1.33 and as "normal" when the normalized biomarker was less than or equal to 1.33. We then performed ROC analysis, using measured GFR as the confirmatory test (Table 4 ). This . According to the FAS concept, this value could be considered as the lower limit for the eGFR reference interval. We therefore compared the effect of the threshold of 60 mL/min/ 1.73 m 2 with 81 mL/min/1.73 m 2 on the consistency with the biomarker reference interval and found that there was about 10% more agreement (p , 0.0001) when the threshold of 81 mL/min/1.73 m 2 was used (Table 5) . This demonstrates that, in the case of children, the reference interval of (0.67-1.33) can be used to diagnose healthy kidney status, corresponding with a GFR threshold of 81 mL/min/1.73 m 2 .
PREDICTION PERFORMANCE OF COMBINED eGFR EQUATIONS
In this section, we focus on eGFR equations that use both Scr and ScysC for children. We compare the combined Schwartz equation (which has not been designed for standardized ScysC) with the combined FAS equation and with the combination of the LM-REV and CAPA equations that are based on the single biomarkers. 31 To compare the performance of different eGFR equations, we took out all serial measurements in the previous data set, resulting in n ¼ 368 children, for whom we used the first measurement only. We have published the performance results of different equations before, [22] [23] but we here add the Scr-based LM-REV equation and the combination of LM-REV with the ScysC-based CAPA equation (see Table 6 ). We also present the results of the univariate and bivariate Schwartz equations, using Scr and ScysC in Table 7 .
The performance of the FAS equation and LM-REV equation is relatively similar (see Table 6 ) overall, but LM-REV performed much worse than FAS in the ,60 mL/min/ 1.73 m 2 subgroup. The univariate and bivariate Schwartz equation performed worse than the other combined equations in the $60 mL/min/1.73 m 2 subgroup, but much better than the other equations in the ,60 mL/min/1.73 m 2 subgroup. This demonstrates that both FAS and Schwartz perform best in the subgroups for which they were originally designed for. It may also suggest that "one" equation to predict GFR in both healthy and diseased children will never be as accurate as separate equations, specifically designed for either of both groups.
To find an explanation for these differences, we plotted the univariate Scr-based equations for Scr/Q crea ¼ 1, Scr/ Q crea ¼ 0.67 and 1.33, the midpoint, and lower and upper limits of the Scr/Q crea reference interval (Fig. 4) . We did the same for the univariate ScysC-based Schwartz, FAS equation, and the CAPA equation, again at midpoint (0.82 mg/ L) and the reference interval limits (Fig. 5) .
For children with mGFR ,60 mL/min/1.73 m 2 , LM-REV does not show good performance, as seen from Table 6 , mainly because the estimated GFR is much too high (bias ¼ 16.6 mL/min/1.73 m 2 ) which can also be observed Abbreviations: mGFR, measured GFR; Scr, serum creatinine. "Abnormal" is defined as marker .1.33 and "normal" as #1.33. mGFR is considered as the confirmatory test. The "threshold" is the value of mGFR corresponding with the most optimal sensitivity at a specificity of 90%. AUC is the area under the ROC curve (an ideal ROC curve has AUC ¼ 1) and SE is the standard error on the AUC. S (%) is the sensitivity at the reported threshold, corresponding to a specificity of 90%; "combined" means the average of both rescaled biomarkers. (Table 1) ; Schwartzcrea, creatinine based revised Schwartz equation (Table 1) , FAScombi, combined Scr/ScysC FAS equation (Table 1) ; FAScombi(Ht), combined Scr/ScysC FAS(height) equation (Table 1 ). All assays are standardized.
from Figure 4 , where (mostly male) children between 4 and 15 years of age with Scr close to the lower limit of the Scr reference interval have estimated GFR from LM-REV mostly higher than estimated GFR from Schwartz or FAS (note that Scr/Q crea ¼ 1.33 corresponds to 81 mL/ min/1.73 m 2 ). Only 3 subjects in this cohort of n ¼ 368 children had Scr .150 mmol/L (or 150/88.4 mg/dL), indicating that the switch in the LM-REV equation has only be applied in 3 occasions. As both FAS and LM-REV overestimate true mGFR when mGFR ,60, LM-REV does that Table 7 . This multiplicative form of the FAS equation is very much alike the combined Schwartz equation. Indeed, linear regression (through the origin) of the height of the child (in m) and Q crea from 72. This shows that on the data at hand, the slope deviates much more from the ideal slope of "1" for Schwartz combi than for FAS Mult . This proportional bias might be a consequence of the noncalibrated cystatin C results used to develop the Schwartz equation.
The combined equations reach P10 close to 45-50% and P30 close to 90-95% in the .60 mL/min/1.73 m 2 subgroup, outperforming the single biomarker equations. All equations have difficulties to accurately predict GFR when GFR ,60 mL/min/1.73 m 2 (except the nonstandardized ScysC-based Schwartz equation). However, we should also realize that all children were from nephrology clinics and only 57/368 ¼ 15% had GFR ,60 mL/min/1.73 m 2 , meaning that it is not very common to see children with GFR ,60 mL/min/1.73 m 2 .
CONCLUSIONS
The height-dependent FAS equation for children up to 14 years of age is essentially equal to the Schwartz equation, though be it with a 7% lower coefficient (0.385 vs 0.413). The difference between both equations becomes important for male adolescents. As the FAS equation allows for the transition to adults, it seems that the Schwartz equation predicts eGFR values that are too low for the (healthy) adolescent population. eGFR equations perform best in the population for whom they were originally designed for, with preference for Schwartz in the kidney diseased children (GFR ,60 mL/min/1.73 m 2 ) and with preference for FAS in healthy and less kidney diseased children (GFR .60 mL/ min/1.73 m 2 ). Biomarkers can be used as such to detect kidney disease when they are outside the reference interval, consistent with a threshold for mGFR for children of about 80 mL/ min/1.73 m 2 . Finally, the combination of biomarkers shows improved prediction performance as compared to single biomarker equations. The multiplicative form of the FAS equation is very similar to the bivariate Schwartz equation.
